Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare® Open-Label Trial

Capo, Jr Jp; Laramée, Christine; Lucente, Vincent; Fakhoury, Allam; Forero-Schwanhaeuser, Sergio

doi:10.1111/j.1742-1241.2007.01644.x

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tolterodine: 1882. Tolterodine 4 mg ER dailyStable but no continued improvement if used 12 additional weeks except in Physical domainDanilova et al [58]Prospective case series57Trospium 15 mg three times daily16 weeksUnknownSexual dysfunction decreasedN/AChapple et al [56]RCT1. Placebo: 2831.…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Impact of urinary incontinence on female sexual health in women during midlife

Chu

Arya

Andy

2015

womens midlife health

View full text Add to dashboard Cite

Sexual health is important to the self worth, emotional well being, and overall quality of life of women in midlife. However, urinary incontinence, which is prevalent in this population, has a negative impact on sexual function. The purpose of this article is to review the impact of urinary incontinence on female sexual dysfunction and discuss the impact of urinary incontinence treatment on sexual function. We carried out a literature review on the effect of stress urinary incontinence and urgency urinary incontinence on sexual health and physiological response, including coital incontinence, satisfaction, desire, orgasm, frequency, and partner relationships. We examined the literature regarding changes in sexual function related to non-surgical and surgical interventions for incontinence. Overall, though studies are lacking and of poor quality, treatment of incontinence has been shown to improve sexual function. Both pelvic muscle training and midurethral slings have been shown to improve sexual function in those with stress urinary incontinence. In urgency urinary incontinence, evidence indicates improvement in sexual function after treatment with anti-muscarinic medications. Coital incontinence commonly improves with treatment of the underlying incontinence subtype. Although problems related to sexual health are complex and involve both psychological and physical factors, it is important to consider treatment of urinary incontinence as part of management of sexual dysfunction.

show abstract

Section: Reviewmentioning

confidence: 99%

“…Fesoterodine likewise was found to improve subjects’ Personal Relationship scores as compared to controls [55]. Other smaller prospective studies have reported some improvement in sexual health following treatment with solifenacin [56] and trospium [57]. Certain trials also found that anti-muscarinic medication may improve coital incontinence.…”

Section: Reviewmentioning

confidence: 99%

Impact of urinary incontinence on female sexual health in women during midlife

Chu

Arya

Andy

2015

womens midlife health

View full text Add to dashboard Cite

show abstract

Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women

Reynolds

McPheeters

Blume

et al. 2015

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin

Doroshyenko

Fuhr

2009

Clinical Pharmacokinetics

View full text Add to dashboard Cite

The succinate salt of solifenacin, a tertiary amine with anticholinergic properties, is used for symptomatic treatment of overactive bladder. Solifenacin peak plasma concentrations of 24.0 and 40.6 ng/mL are reached 3-8 hours after long-term oral administration of a 5 or 10 mg solifenacin dose, respectively. Studies in healthy adults have shown that the drug has high absolute bioavailability of about 90%, which does not decrease with concomitant food intake. Solifenacin has an apparent volume of distribution of 600 L, is 93-96% plasma protein bound, and probably crosses the blood-brain barrier. Solifenacin is eliminated mainly through hepatic metabolism via cytochrome P450 (CYP) 3A4, with about only 7% (3-13%) of the dose being excreted unchanged in the urine. Solifenacin metabolites are unlikely to contribute to clinical solifenacin effects. In healthy adults, total clearance of solifenacin amounts to 7-14 L/h. The terminal elimination half-life ranges from 33 to 85 hours, permitting once-daily administration. Urinary excretion plays a minor role in the elimination of solifenacin, resulting in renal clearance of 0.67-1.51 L/h. Solifenacin does not influence the activity of CYP1A1/2, 2C9, 2D6 and 3A4, and shows a weak inhibitory potential for CYP2C19 and P-glycoprotein in vitro; however, clinical drug-drug interactions with CYP2C19 and P-glycoprotein substrates are very unlikely. Exposure to solifenacin is increased about 1.2-fold in elderly subjects and about 2-fold in subjects with moderate hepatic and severe renal impairment, as well as by coadministration of the potent CYP3A4 inhibitor ketoconazole 200 mg/day. The full therapeutic effects of solifenacin occur after 2-4 weeks of treatment and are maintained upon long-term therapy. Although solifenacin pharmacokinetics display linearity at doses of 5-40 mg, no obvious dose dependency was observed in efficacy and tolerability studies. The efficacy of solifenacin (5 or 10 mg/day) is at least equal to that of extended-release (ER) tolterodine (4 mg/day) in reducing the mean number of micturitions per 24 hours and urgency episodes, and in increasing the volume voided per micturition. Solifenacin (5 mg/day) appears to be superior to ER tolterodine (4 mg/day) in reducing incontinence episodes (mean -1.30 vs -0.90, p = 0.018) and is superior to propiverine (20 mg/day) at the dose of 10 mg/day in reducing urgency (-2.30 vs -2.78, p = 0.012) and nocturia episodes. Based on withdrawal rates due to adverse effects during the 52-week treatment period, solifenacin appears to have better tolerability than immediate-release (IR) oxybutynin 10-15 mg/day and IR tolterodine 4 mg/day. With regard to the pharmacokinetics of solifenacin, and for safety reasons, doses exceeding 5 mg/day are not recommended for patients with moderate hepatic impairment (Child-Pugh score 7-9), patients with severe renal impairment (creatinine clearance <30 mL/min) and subjects undergoing concomitant therapy with CYP3A4 inhibitors.

show abstract

Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare® Open-Label Trial

Abstract: Although numbers were small, Hispanics receiving solifenacin for OAB reported improvement from baseline in symptom bother and HRQoL, as assessed by three independent PRO measures.

Cited by 3 publications

References 25 publications

Impact of urinary incontinence on female sexual health in women during midlife

Impact of urinary incontinence on female sexual health in women during midlife

Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women

Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin

Contact Info

Product

Resources

About